By Scott Gottlieb (original source Health Affairs)
“In recent years, considerable bipartisan Congressional action, leadership from both Democratic and Republican administrations, and broad-based multistakeholder collaborations have focused on improving the tools and regulatory processes at the Food and Drug Administration (FDA), other government agencies, and public-private collaborations to support more efficient and timely development of new medical technologies. Enhanced funding through user fees and the bipartisan Twenty-First Century Cures legislation have supported a robust and better-resourced FDA and enabled science-driven collaborations in a range of areas including innovative clinical trials, “patient-focused” drug development, and greater clarity around standards for regulatory approval of new technologies.”
Click here to read more
Ambassador Deborah Birx, MD, Unveils Urgent Insights on Avian Flu, COVID-19, and HMPV
On January 13, 2025, the Animal and Plant Health Inspection Service (APHIS), part of the United States Department of Agriculture (USDA), announced that it has…
Thought Leader: Deborah Birx
Dr. Scott Gottlieb to keynote MM+M Transform in April
Former FDA commissioner, Dr. Scott Gottlieb will take the stage for the brand’s 11th annual spring conference. Dr. Scott Gottlieb, who served as 23rd commissioner…
Thought Leader: Scott Gottlieb
More needs to be done to prevent bird flu outbreak, says Dr. Scott Gottlieb
Dr. Scott Gottlieb, former FDA Commissioner, joins CNBC’s ‘Squawk Box’ to discuss concerns around a bird flu outbreak in the U.S. To host Dr. Gottlieb…
Thought Leader: Scott Gottlieb
